These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 29241903

  • 41. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Bae JH, Kim S, Park EG, Kim SG, Hahn S, Kim NH.
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
    [Abstract] [Full Text] [Related]

  • 42. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials.
    Silverii GA, Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M.
    Endocrine; 2020 Sep; 69(3):504-507. PubMed ID: 32236820
    [Abstract] [Full Text] [Related]

  • 43. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
    Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators.
    N Engl J Med; 2013 Oct 03; 369(14):1317-26. PubMed ID: 23992601
    [Abstract] [Full Text] [Related]

  • 44. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
    Kalra S, Unnikrishnan AG, Agrawal N, Singh AK.
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep 03; 5(3):197-202. PubMed ID: 21913883
    [Abstract] [Full Text] [Related]

  • 45. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
    Chen M, Liu Y, Jin J, He Q.
    Ren Fail; 2016 Sep 03; 38(4):581-7. PubMed ID: 26915531
    [Abstract] [Full Text] [Related]

  • 46. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
    Kaneko M, Narukawa M.
    Diabetes Res Clin Pract; 2016 Jun 03; 116():171-82. PubMed ID: 27321333
    [Abstract] [Full Text] [Related]

  • 47. Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.
    Vaduganathan M, Singh A, Sharma A, Januzzi JL, Scirica BM, Butler J, Zannad F, McGuire DK, Cannon CP, Bhatt DL.
    Am J Cardiol; 2020 May 15; 125(10):1577-1581. PubMed ID: 32245636
    [Abstract] [Full Text] [Related]

  • 48. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
    Golightly LK, Drayna CC, McDermott MT.
    Clin Pharmacokinet; 2012 Aug 01; 51(8):501-14. PubMed ID: 22686547
    [Abstract] [Full Text] [Related]

  • 49. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.
    Scheen A.
    Expert Opin Drug Saf; 2013 Jul 01; 12(4):545-57. PubMed ID: 23621381
    [Abstract] [Full Text] [Related]

  • 50. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials.
    Dicembrini I, Montereggi C, Nreu B, Mannucci E, Monami M.
    Diabetes Res Clin Pract; 2020 Jan 01; 159():107981. PubMed ID: 31870827
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
    Kridin K, Bergman R.
    JAMA Dermatol; 2018 Oct 01; 154(10):1152-1158. PubMed ID: 30090931
    [Abstract] [Full Text] [Related]

  • 54. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.
    Fu AZ, Johnston SS, Ghannam A, Tsai K, Cappell K, Fowler R, Riehle E, Cole AL, Kalsekar I, Sheehan J.
    Diabetes Care; 2016 May 01; 39(5):726-34. PubMed ID: 26740636
    [Abstract] [Full Text] [Related]

  • 55. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
    Baksh SN, McAdams-DeMarco M, Segal JB, Alexander GC.
    Pharmacoepidemiol Drug Saf; 2018 Jun 01; 27(6):660-667. PubMed ID: 29655237
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ, Chen HT, Kuo SC, Ou SM, Chen YT.
    J Am Med Dir Assoc; 2016 Jan 01; 17(1):59-64. PubMed ID: 26612484
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.